RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.

As Nerve Pain Prescriptions Spike, Pipeline Turns to Relieving Osteoarthritic Pain

January 12, 2018
Centrexion Therapeutics is dedicating $67 million to Phase 3 studies for relieving chronic knee pain.

A PPM Brief

Centrexion Therapeutics (Boston, MA) is dedicating $67 million to Phase 3 programs for relieving chronic knee pain due to osteoarthritis (OA). The biotech's synthetic at-site injection of trans-capsaicin, known as CNTX-4975, has performed well in clinical trials conducted to date, providing substantial, quick-onset pain reduction in patients with moderate to severe OA pain, according to a company release. Significant reductions in knee stiffness and improvements in joint function have also been found.

The non-opioid pipeline medication targets the capsaicin receptor, inactivating its local pain fibers transmitting signals to the brain, while maintaining the patient’s normal nerve function/sensation and avoiding risks of other potential treatments, notes the release.  

In related news, as previously reported in PPM, a study by the Heritage College of Osteopathic Medicine at Ohio University showed that gabapentinoid prescriptions, indicated for relieving nerve pain associated with conditions such as osteoarthritis, have more than tripled between 2002 and 2015. Centrexion' s therapeutic may offer a future alternative to these prescriptions.

 

Update: Centrexion announced on January 16, 2018, that FDA has granted fast-track status for CNTX-4975.

Last updated on: January 18, 2018
Continue Reading:
Botox Injections Provide Pain Relief for Knee Osteoarthritis
SHOW MAIN MENU
SHOW SUB MENU